Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9844720rdf:typepubmed:Citationlld:pubmed
pubmed-article:9844720lifeskim:mentionsumls-concept:C0007600lld:lifeskim
pubmed-article:9844720lifeskim:mentionsumls-concept:C0086418lld:lifeskim
pubmed-article:9844720lifeskim:mentionsumls-concept:C0010453lld:lifeskim
pubmed-article:9844720lifeskim:mentionsumls-concept:C0521432lld:lifeskim
pubmed-article:9844720lifeskim:mentionsumls-concept:C0597177lld:lifeskim
pubmed-article:9844720lifeskim:mentionsumls-concept:C0033268lld:lifeskim
pubmed-article:9844720pubmed:issue5-6lld:pubmed
pubmed-article:9844720pubmed:dateCreated1999-3-11lld:pubmed
pubmed-article:9844720pubmed:abstractTextThe human megakaryocytic cell line CMK was positive for the expression of platelet glycoprotein(GP) IIb/IIIa but few cells were positive for GPIb. To establish a GPIb-positive CMK subclone, GPIb-positive CMK cells were purified, micromanipulated and cloned, but resulting sublines were all negative for GPIb expression. The combined presence of interleukin-3 (IL-3) and the anti-virus agent ribavirin strongly induced expression of GPIb on the cells. However, the megakaryocyte growth and development factor (MGDF)/thrombopoietin (TPO) failed to enhance GPIb expression. CMK themselves and particles are negative for GPIb expression. To utilize these particles as platelet substitutes, further appropriate culture systems are necessary.lld:pubmed
pubmed-article:9844720pubmed:languageenglld:pubmed
pubmed-article:9844720pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9844720pubmed:citationSubsetIMlld:pubmed
pubmed-article:9844720pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9844720pubmed:statusMEDLINElld:pubmed
pubmed-article:9844720pubmed:monthNovlld:pubmed
pubmed-article:9844720pubmed:issn1073-1199lld:pubmed
pubmed-article:9844720pubmed:authorpubmed-author:AbeHHlld:pubmed
pubmed-article:9844720pubmed:authorpubmed-author:YamaguchiMMlld:pubmed
pubmed-article:9844720pubmed:authorpubmed-author:FujiharaMMlld:pubmed
pubmed-article:9844720pubmed:authorpubmed-author:SekiguchiSSlld:pubmed
pubmed-article:9844720pubmed:authorpubmed-author:NiwaKKlld:pubmed
pubmed-article:9844720pubmed:authorpubmed-author:IkebuchiKKlld:pubmed
pubmed-article:9844720pubmed:issnTypePrintlld:pubmed
pubmed-article:9844720pubmed:volume26lld:pubmed
pubmed-article:9844720pubmed:ownerNLMlld:pubmed
pubmed-article:9844720pubmed:authorsCompleteYlld:pubmed
pubmed-article:9844720pubmed:pagination549-58lld:pubmed
pubmed-article:9844720pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:9844720pubmed:meshHeadingpubmed-meshheading:9844720-...lld:pubmed
pubmed-article:9844720pubmed:meshHeadingpubmed-meshheading:9844720-...lld:pubmed
pubmed-article:9844720pubmed:meshHeadingpubmed-meshheading:9844720-...lld:pubmed
pubmed-article:9844720pubmed:meshHeadingpubmed-meshheading:9844720-...lld:pubmed
pubmed-article:9844720pubmed:meshHeadingpubmed-meshheading:9844720-...lld:pubmed
pubmed-article:9844720pubmed:meshHeadingpubmed-meshheading:9844720-...lld:pubmed
pubmed-article:9844720pubmed:meshHeadingpubmed-meshheading:9844720-...lld:pubmed
pubmed-article:9844720pubmed:year1998lld:pubmed
pubmed-article:9844720pubmed:articleTitlePlatelet-like particle production from cultured human megakaryocytic cell line.lld:pubmed
pubmed-article:9844720pubmed:affiliationHokkaido Red Cross Blood Center, Japan.lld:pubmed
pubmed-article:9844720pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9844720pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed